Immurons Travelan product has experienced significant growth in sales

Immuron Limited (ASX: IMC) reported significant sales growth for Travelan, its over-the-counter immune supplement targeting pathogenic bacteria and toxins in the gastrointestinal tract. Sales for the December 2024 Quarter surged 90% to AUD 1.851 million, compared to AUD 1.007 million in the September 2024 Quarter, marking a 315% increase over the December 2023 Quarter. Half-year sales climbed 54% to AUD 2.858 million, compared to AUD 1.853 million in the December 2023 Half Year.

North American sales grew 43% in the December 2024 Quarter to AUD 0.652 million from AUD 0.456 million in the September 2024 Quarter, reflecting a 141% increase over the December 2023 Quarter. Half-year North American sales rose 57% to AUD 1.108 million, with the USA and Canada contributing AUD 0.731 million and AUD 0.376 million, respectively. This robust growth highlights Travelan’s expanding market presence and customer demand.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com